Analysis and Opinions about REGN-Q

A higher-risk/return play. This biotech has several core products generating good free cash flow. They’re partnering with Sanofi on Dupixent to treatment severe atopic dermatitis and potentially severe asthma. They also have another drug to treat specific eye diseases. REGN boasts various late-stage drug trials.
Regeneron is a new Top Pick for us, driven by the valuation having compressed significantly on concerns over U.S. Medicare Part B drug pricing policy proposals. We believe these are more than reflected in the current price.Their dermatitis drug is getting traction. This stock has been beat up for the wrong reasons. This (Analysts’ price target is $389.38)

A higher-risk/return play. This biotech has several core products generating good free cash flow. They’re partnering with Sanofi on Dupixent to treatment severe atopic dermatitis and potentially severe asthma. They also have another drug to treat specific eye diseases. REGN boasts various late-stage drug trials.
Regeneron is a new Top Pick for us, driven by the valuation having compressed significantly on concerns over U.S. Medicare Part B drug pricing policy proposals. We believe these are more than reflected in the current price.Their dermatitis drug is getting traction. This stock has been beat up for the wrong reasons. This (Analysts’ price target is $389.38)

Diversity is key. Large biotech has been beat up. Speculation that Novartis is a competitor, but it's at early stages for them. REGN does have a drug for a niche market. Correction is in part because of Novartis speculation plus medicare reimbursement. Current multiple around 13x, you can buy it, but buy it in a basket.

Diversity is key. Large biotech has been beat up. Speculation that Novartis is a competitor, but it's at early stages for them. REGN does have a drug for a niche market. Correction is in part because of Novartis speculation plus medicare reimbursement. Current multiple around 13x, you can buy it, but buy it in a basket.

He likes biotech as a space, and it has recently re-accelerated. This company has a number of key drugs. Their major drug is Eylea for macular degeneration, a multi-, multi-billion-dollar drug. However, they have a newer drug, which is aimed at the allergy market, which could potentially be a $10 billion drug. This company will double its earnings in the next 3 years and is not dependent on one product. (Analysts’ price target is $438.)

He likes biotech as a space, and it has recently re-accelerated. This company has a number of key drugs. Their major drug is Eylea for macular degeneration, a multi-, multi-billion-dollar drug. However, they have a newer drug, which is aimed at the allergy market, which could potentially be a $10 billion drug. This company will double its earnings in the next 3 years and is not dependent on one product. (Analysts’ price target is $438.)

Comments

Regeneron Pharmaceuticals Inc(REGN-Q) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Regeneron Pharmaceuticals Inc is calculated according
to the stock experts' signals. A high score means experts
mostly recommend to buy the stock while a low score means
experts mostly recommend to sell the stock.

Regeneron Pharmaceuticals Inc(REGN-Q) Frequently Asked Questions

What is Regeneron Pharmaceuticals Inc stock symbol?

Regeneron Pharmaceuticals Inc is a American stock, trading under the symbol
REGN-Q on the NASDAQ
(REGN).
It is usually referred to as
NASDAQ:REGN or REGN-Q

Is Regeneron Pharmaceuticals Inc a buy or a sell?

In the last year, there was no coverage of Regeneron Pharmaceuticals Inc
published on Stockchase.

Why is Regeneron Pharmaceuticals Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop.
Read stock experts’ recommendations
for help on deciding if you should buy, sell or hold the stock.

Is Regeneron Pharmaceuticals Inc worth watching?

0 stock analyst
on Stockchase covered Regeneron Pharmaceuticals Inc In the last year.
It is a trending stock that is worth watching.

What is Regeneron Pharmaceuticals Inc stock price?

On 2020-06-05, Regeneron Pharmaceuticals Inc (REGN-Q)
stock closed at a price of $597.

Stockchase, in its reporting on what has been discussed by individuals on business
television programs (in particular Business News Network), neither recommends nor
promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood
from the experts’ comments.
We are human and can make mistakes,
help us fix any errors. If you see something that you know is not right or if there is a
problem with the site, feel free to email us at :
hello@stockchase.com.